Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine.
Nagel
J M
JM
Mansmann
U
U
Wegscheider
K
K
Röhmel
J
J
D015331:Cohort Studies; D015986:Confounding Factors, Epidemiologic; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D007333:Insulin Resistance / Q000502:physiology*; D049528:Insulin, Long-Acting; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D012307:Risk Factors; D012449:Safety
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine